26 janvier 2017: Prof. Michael Platten

Jeudi 26 janvier 2017
12h30, CMU - C150
  
Prof. Dr. med. Michael PLATTEN
Chairman, Department of Neurology
University Hospital Mannheim, Heidelberg University
Head, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology German Cancer Research Center

«Targeting driver mutations in gliomas using immunotherapy - from bench to bedside and back»

With the successes of checkpoint inhibitors and engineered T cells cancer immunotherapy has made major progress in recent years. Personalization and tumoral heterogeneity have remained major challenges in the field. This presentations highlights the potential of targeting driver mutations in cancer to circumvent these challenges exemplified by preclinical and clinical studies targeting driver mutations in gliomas.

«A pioneer in the field of brain tumor immunology, sailing between auto-immunity and tumor immunity, moving from neurology to neuro-oncology, always with the same high level of perception and lucidity.»

Prof. Pierre-Yves DIETRICH, Host
Département de médecine interne des spécialités, Faculté de Médecine, UNIGE
Médecin-chef du Service d'oncologie, HUG

-----------

Michael PLATTEN
Biographical Sketch

Education/ Training

1990-1998: Studies of Medicine (MD), Bonn University, London University and Harvard Medical School, Germany

1999-2006: Residency and Board Certification in Neurology, Department of Neurology, University of Tübingen, Germany

2002–2004: Post-doctoral Research Fellow, Department of Neurological Sciences, Stanford University, USA

Positions and Employment

2006: Attending in Neurology, Department of Neurology, University of Tübingen, Germany

2007- : Senior Attending and Vice Chair, Department of Neurooncology, Heidelberg University, Germany

2007-2013: Head, Helmholtz University Young Investigator Group Experimental Neuroimmunology, DKFZ, Germany

2010: Professor of Neuroimmunology, Heidelberg University, Germany

2013- : Head CCU Neuroimmunology and Brain Tumor Immunology, DKFZ, Germany

2014-2016: Vice Chair, Department of Neurology, University Hospital Heidelberg, Germany

2015- : Full Professor of Neurology, Heidelberg University, Germany

2016- : Chairman, Department of Neurology, University Hospital Mannheim, Germany

Honors

2012: Sir Hans Krebs Award

2011: Chica and Heinz Schaller Award

2010: Heinrich Pette Award of the German Neurological Society

2006: Helmut Bauer Award for Multiple Sclerosis Research

2002-2004: Emmy Noether Fellow of the German Research Foundation

2000-2002: Jung Fellow

2000: EANO Basic Young Scientist Award

1998: ERASMUS Fellow

1995: BMEP Fellow

Research Field
Neurooncology – Neuroimmunology – Glioma Immunotherapy – Cancer Vaccines

Other Experience and Professional Memberships

German Academy of Neurology (DGN)
American Academy of Neurology (AAN)
German Cancer Society (DKG)
Steering Board DKG Neurooncology Working Group (NOA)
European Association for Neuro-Oncology (EANO)
European Organisation for the Research and Treatment of Cancer Brain Tumor Group (EORTC-BTG), General Assembly of the EORTC
Society for Neuro-Oncology (SNO)
Faculty of the German Cancer Consortium
Leading Investigator of the NOA-16 trial (IDH1 vaccine in gliomas)

Inventions

A method of modulating cellular activity and agents useful for the same

      US 7531575 B2

Method of modulating T cell functioning

      WO 2006076580 A2

Trp/his exchange and kynurenine induced trp transport

      WO 2008108994 A1

Means and methods for treating and/or preventing natural Ahr ligand-dependent cancer

      WO 2013034685 A1

Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers

      WO 2013/102641 A1, PCT/EP2013/050048

Treatment of Kynurenin-producing Tumors with AhR Antagonists

      DKFZ, P1014, PCT/EP2012/067504, US 2014/0294860 A1

Method for the Detection of Antigen Presentation

      DKFZ, P1203, EPA 14190538.0

Selected peer-reviewed publications (in chronological order)

5 most significant publications selected from 107 peer-reviewed publications.

Bunse L*, Schumacher T*, Sahm S*, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Proximity ligation assay evaluates presentation of mutant isocitrate dehydrogenase 1 in gliomas. J Clin Invest 2015, 125:1-14. *equal contribution

Schumacher T*, Bunse L*, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumor immunity. Nature 2014,512:324-327. *equal contribution

Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Endothelial protein kinase Cβ as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2013, 110:14735-14740.

Opitz CA*, Litzenburger UM*, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature 2011, 478:197-203. *equal contribution

Platten M*, Ho PP*, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310:850-855. *equal contribution